Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADILW), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adial Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adial Pharmaceuticals's position in the market.
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) has officially requested FDA expedited review for its lead drug candidate, AD04, aimed at treating Alcohol Use Disorder (AUD). The request is based on the unmet medical need for effective treatments, especially amid escalating AUD issues due to the COVID-19 pandemic. CEO William Stilley highlighted the ongoing Phase 3 clinical trial progress and the promising results from the Phase 2 trial, reinforcing AD04's potential. The drug also holds promise for additional addictive disorders, further emphasizing the importance of regulatory support.
Adial Pharmaceuticals (NASDAQ:ADIL; ADILW) announced its participation in the H.C. Wainwright Annual Global Investment Conference from September 14-16, 2020. CEO William Stilley will present on September 16 at 1:30 p.m. ET, with a live webcast available. Adial focuses on addiction treatments, with its lead drug AD04 targeting Alcohol Use Disorder (AUD) via a genetic approach. A Phase 2b trial showed significant effectiveness in reducing drinking behaviors without serious safety concerns. AD04 may also help treat other addictions such as opioids and gambling.
Adial Pharmaceuticals (NASDAQ:ADIL, ADILW) announced its participation in the LD Micro 500 Virtual Investor Conference from September 1-4, 2020. The CEO, William Stilley, will present on September 2 at 3:20 p.m. ET, with a live webcast available. The conference showcases key players in the small and micro-cap sector, featuring one-on-one meetings via video calls. Adial is focused on developing treatments for addictions, particularly its lead product AD04, currently in Phase 3 trials for Alcohol Use Disorder. For more information, visit Adial's website.